An Update On the Clinical Development of Dalcetrapib (RO4607381), a Cholesteryl Ester Transfer Protein Modulator That Increases HDL Cholesterol Levels

• Baigent C , KeechA, KearneyPMet al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet , 366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Fruchart JC , SacksF, HermansMPet al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. , 102(Suppl. 10), 1K–34K (2008).
   PubMed Web of Science ®Google Scholar
• Castelli WP . Epidemiology of coronary heart disease: the Framingham study. Am. J. Med., 76(2A), 4–12 (1984).
   PubMed Web of Science ®Google Scholar
• Barter PJ , CaulfieldM, ErikssonMet al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. , 357(21), 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• deGoma EM , deGomaRL, RaderDJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., 51(23), 2199–2211 (2008).
   PubMed Web of Science ®Google Scholar
• Barter PJ , JonesME. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J. Lipid Res., 21(2), 238–249 (1980).
   PubMed Web of Science ®Google Scholar
• Chapman MJ , Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J., 31(2), 149–164 (2010).
   PubMed Web of Science ®Google Scholar
• Schwartz CC , Van den Broek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res., 45(9), 1594–1607 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y , Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest., 115(10), 2870–2874 (2005).
   PubMed Web of Science ®Google Scholar
• Nijstad N , GautierT, BriandF, RaderDJ, TietgeUJ. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology, 140(3), 1043–1051 (2011).
   PubMed Web of Science ®Google Scholar
• Niesor EJ , MaggC, OgawaNet al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. , 51(12), 3443–3454 (2010).
   PubMed Web of Science ®Google Scholar
• Teslovich TM , MusunuruK, SmithAVet al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature , 466(7307), 707–713 (2010).
   PubMed Web of Science ®Google Scholar
• Kaess BM , TomaszewskiM, BraundPSet al. Large-scale candidate gene analysis of HDL particle features. PLoS ONE , 6(1), E14529 (2011).
   PubMed Web of Science ®Google Scholar
• Thompson A et al. , Di Angelantonio E, Sarwar N Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA, 299(23), 2777–2788 (2008).
   PubMed Web of Science ®Google Scholar
• Barzilai N , AtzmonG, SchechterCet al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA , 290(15), 2030–2040 (2003).
   PubMed Web of Science ®Google Scholar
• Zhong S , SharpDS, GroveJSet al. Increased coronary heart disease in Japanese–American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. , 97(12), 2917–2923 (1996).
   PubMed Web of Science ®Google Scholar
• Morehouse LA , SugarmanED, BourassaPAet al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. , 48(6), 1263–1272 (2007).
   PubMed Web of Science ®Google Scholar
• Okamoto H , YonemoriF, WakitaniK, MinowaT, MaedaK, ShinkaiH. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature, 406(6792), 203–207 (2000).
   PubMed Web of Science ®Google Scholar
• Plump AS , Masucci-MagoulasL, BruceC, BisgaierCL, BreslowJL, TallAR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol., 19(4), 1105–1110 (1999).
   PubMed Web of Science ®Google Scholar
• Chapman MJ , GinsbergHN, AmarencoPet al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. , 32(11), 1345–1361 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang LH , KamannaVS, ZhangMC, KashyapML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid Res., 49(6), 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Tunaru S , KeroJ, SchaubAet al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. , 9(3), 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor AJ , VillinesTC, StanekEJet al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. , 361(22), 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Lee JM , RobsonMD, YuLMet al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol. , 54(19), 1787–1794 (2009).
   PubMed Web of Science ®Google Scholar
• Investigators AH . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. (2011).
   Google Scholar
• Keech A , SimesRJ, BarterPet al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet , 366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN , ElamMB, LovatoLCet al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. , 362(17), 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Scott R , O‘BrienR, FulcherGet al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care , 32(3), 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• Lee M , SaverJL, TowfighiA, ChowJ, OvbiageleB. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis, 217(2), 492–498 (2011).
   PubMed Web of Science ®Google Scholar
• Betteridge DJ . CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam. Clin. Pharmacol., 23(6), 675–679 (2009).
   PubMed Web of Science ®Google Scholar
• Nissen SE , TardifJC, NichollsSJet al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. , 356(13), 1304–1316 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon CP , ShahS, DanskyHMet al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. , 363(25), 2406–2415 (2010).
   PubMed Web of Science ®Google Scholar
• Okamoto H , IwamotoY, MakiM, SotaniT, YonemoriF, WakitaniK. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur. J. Pharmacol., 466(1–2), 147–154 (2003).
   PubMed Web of Science ®Google Scholar
• Okamoto H , MiyaiA, SasaseTet al. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma. Clin. Chim. Acta , 375(1–2), 92–98 (2007).
   PubMed Web of Science ®Google Scholar
• Barter PJ . Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl., 3(4), 39–47 (2002).
   PubMed Web of Science ®Google Scholar
• Niesor EJ . Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr. Opin. Lipidol., 22(4), 288–295 (2011).
   PubMed Web of Science ®Google Scholar
• Rye KA , JauhiainenM, BarterPJ, EhnholmC. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J. Lipid Res., 39(3), 613–622 (1998).
   PubMed Web of Science ®Google Scholar
• Shimoji E , ZhangB, FanP, SakuK. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis, 172(2), 247–257 (2004).
   PubMed Web of Science ®Google Scholar
• Derks M , AbtM, PhelanMet al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug–drug interactions. J. Clin. Pharmacol. , 50(10), 1188–1201 (2010).
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ , HovinghGKet al., El Harchaoui K Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler. Thromb. Vasc. Biol., 25(9), E133–E134 (2005).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , MillerM, NiesorEJ, BurgessT, KallendD, SteinEA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism in dyslipidemic patients: results of a Phase 2B dose-ranging study. J. Am. Coll. Cardiol., 55(10A), A47 (2010).
   Google Scholar
• Zhang B , FanP, ShimojiEet al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler. Thromb. Vasc. Biol. , 24(10), 1910–1915 (2004).
   PubMed Web of Science ®Google Scholar
• Khera AV , CuchelMet al., de la Llera-Moya M Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med., 364(2), 127–135 (2011).
   PubMed Web of Science ®Google Scholar
• Rosenson RS . Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovasc. Drugs Ther., 24(1), 71–75 (2010).
   PubMed Web of Science ®Google Scholar
• Kobayashi J , OkamotoH, OtabeM, BujoH, SaitoY. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis, 162(1), 131–135 (2002).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , MillerM, NiesorEJ, BurgessT, KallendD, SteinEA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a Phase IIb dose-ranging study. Am. Heart J., 163(3), 515–521, 521 E511–E513 (2012).
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L , KlingJ, PaglerTet al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. , 30(7), 1430–1438 (2010).
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L , MatsuuraF, WangNet al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. , 27(5), 1132–1138 (2007).
   PubMed Web of Science ®Google Scholar
• Castro-Perez J , BriandF, GagenKet al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. , 52(11), 1965–1973 (2011).
   PubMed Web of Science ®Google Scholar
• Huang Z , InazuA, NoharaA, HigashikataT, MabuchiH. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond.)., 103(6), 587–594 (2002).
   PubMed Web of Science ®Google Scholar
• Bots ML , VisserenFL, EvansGWet al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet , 370(9582), 153–160 (2007).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ , TuzcuEM, BrennanDM, TardifJC, NissenSE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation, 118(24), 2506–2514 (2008).
   PubMed Web of Science ®Google Scholar
• Shinkai H , MaedaK, YamasakiT, OkamotoH, UchidaI. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J. Med. Chem., 43(19), 3566–3572 (2000).
   PubMed Web of Science ®Google Scholar
• Shinkai H . Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Exp. Opin. Ther. Pat., 19(9), 1229–1237 (2009).
   PubMed Web of Science ®Google Scholar
• Hope HR , HeuvelmanD, DuffinKet al. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J. Lipid Res. , 41(10), 1604–1614 (2000).
   PubMed Web of Science ®Google Scholar
• Kuhlmann O , HeinigK. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica, 41(5), 430–436 (2011).
   PubMed Web of Science ®Google Scholar
• Niesor EJ , Von der Mark E, Brousse M, Maugeais C. Inhibition of cholesteryl ester transfer protein (CETP): different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR). Atherosclerosis, 199(1), (2008).
   Google Scholar
• Perez A , WrightMB, MaugeaisCet al. MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages. Toxicol. In Vitro , 24(3), 745–750 (2010).
   PubMed Web of Science ®Google Scholar
• Ranalletta M , BieriloKK, ChenYet al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. , 51(9), 2739–2752 (2010).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ , KuivenhovenJA, StalenhoefAFet al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose–response study. Circulation , 105(18), 2159–2165 (2002).
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA et al. , de Grooth GJ, Kawamura H Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol., 95(9), 1085–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Stein EA , StroesES, SteinerGet al. Safety and tolerability of dalcetrapib. Am. J. Cardiol. , 104(1), 82–91 (2009).
   PubMed Web of Science ®Google Scholar
• Stein EA , RothEM, RhyneJM, BurgessT, KallendD, RobinsonJG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur. Heart J., 31(4), 480–488 (2010).
   PubMed Web of Science ®Google Scholar
• Derks M , Anzures-CabreraJ, TurnbullL, PhelanM. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, Phase I study. Clin. Drug Investig., 31(5), 325–335 (2011).
   PubMed Web of Science ®Google Scholar
• Schwartz GG , OlssonAG, BallantyneCMet al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. , 158(6), 896–901 E893 (2009).
   PubMed Web of Science ®Google Scholar
• Derks M , KawamuraH, AbtM, Meneses-LorenteG, PhelanM, IshikawaT. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three Phase I, single-dose crossover studies in healthy volunteers. Clin. Ther., 33(6), 754–765 (2011).
   PubMed Web of Science ®Google Scholar
• Krishna R , BergmanAJ, JinBet al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. , 84(6), 679–683 (2008).
   PubMed Web of Science ®Google Scholar
• Derks M , FowlerS, KuhlmannO. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin. Ther., 31(3), 586–599 (2009).
   PubMed Web of Science ®Google Scholar
• Derks M , FowlerS, KuhlmannO. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr. Med. Res. Opin., 25(4), 891–902 (2009).
   PubMed Web of Science ®Google Scholar
• Derks M , AbtM, ParrG, Meneses-LorenteG, YoungAM, PhelanM. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin. Investig. Drugs, 19(10), 1135–1145 (2010).
   PubMed Web of Science ®Google Scholar
• Derks M , AbtM, PhelanM. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. Br. J. Clin. Pharmacol., 70(6), 825–833 (2010).
   PubMed Web of Science ®Google Scholar
• Fayad ZA , ManiV, WoodwardMet al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet , 378(9802), 1547–1559 (2011).
   PubMed Web of Science ®Google Scholar
• Kontush A , ChapmanMJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev., 58(3), 342–374 (2006).
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF , DavidsonMH, RobinsonJGet al. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes. Metab. , 14(1), 30–39 (2011).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ , DuivenvoordenR, DeanfieldJet al. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr. Med. Res. Opin. , 27(1), 141–150 (2011).
   PubMed Web of Science ®Google Scholar
• Luscher TF , TaddeiS, KaskiJCet al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. , 33(7), 857–865 (2012).
   PubMed Web of Science ®Google Scholar
• Hermann F , EnseleitF, SpiekerLEet al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb. Res. , 123(3), 460–465 (2009).
   PubMed Web of Science ®Google Scholar
• Fayad ZA , ManiV, WoodwardMet al. Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am. Heart J. , 162(2), 214.e2–221.e2 (2011).
   PubMed Web of Science ®Google Scholar
• Tardif JC , LesageF, HarelF, RomeoP, PressaccoJ. Imaging biomarkers in atherosclerosis trials. Circ. Cardiovasc. Imaging, 4(3), 319–333 (2011).
   PubMed Web of Science ®Google Scholar
• Barter P . Lessons learned from the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Am. J. Cardiol., 104(Suppl. 10), E10–E15 (2009).
   PubMed Web of Science ®Google Scholar
• Clerc RG , StaufferA, WeibelFet al. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J. Hypertens. , 28(8), 1676–1686 (2010).
   PubMed Web of Science ®Google Scholar
• Stroes ES , KasteleinJJ, BenardeauAet al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br. J. Pharmacol. , 158(7), 1763–1770 (2009).
   PubMed Web of Science ®Google Scholar
• Sofat R , HingoraniAD, SmeethLet al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation , 121(1), 52–62 (2010).
   PubMed Web of Science ®Google Scholar
• Cuchel M , Lund-KatzSet al., de la Llera-Moya M Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Arterioscler. Thromb. Vasc. Biol., 30(3), 526–532 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ , BrewerHB, KasteleinJJet al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA , 306(19), 2099–2109 (2011).
   PubMed Web of Science ®Google Scholar
• Robinson JG . Dalcetrapib: a review of Phase II data. Expert Opin. Investig. Drugs, 19(6), 795–803 (2010).
   PubMed Web of Science ®Google Scholar

Patent

• Japan Tobacco Inc. WO1998035937 (1998) CETP activity inhibitors.
   Google Scholar

Websites

• Niacin plus statin to prevent vascular events. http://clinicaltrials.gov/ct2/show/NCT00120289
   Google Scholar
• Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. http://clinicaltrials.gov/ct2/show/NCT00461630?term=NCT00461630&rank=1
   Google Scholar
• REVEAL: randomized evaluation of the effects of anacetrapib through lipid-modification. http://clinicaltrials.gov/ct2/show/NCT01252953?term=NCT01252953&rank=1
   Google Scholar
• Roche press release. Roche and Japan Tobacco enter agreement on a novel approach to treat high lipid levels in the blood. Media release, 20 October 2004. www.roche.com/med-cor-2004-10-20
   Google Scholar
• NIH press release. NIH stops clinical trial on combination cholesterol treatment. Media release, 26 May 2011. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792
   Google Scholar
• Clinical Trial Service Unit press realease. Launch of major international study to test new drug combination to cut cardiovascular disease. HPS2-THRIVE press release. www.ctsu.ox.ac.uk/pressreleases/2006-05-31/hps2-thrive-press-release
   Google Scholar
• CETPi forum. www.cetpiforum.org
   Google Scholar